TransCode Therapeutics (NASDAQ:RNAZ) Issues Quarterly Earnings Results

TransCode Therapeutics (NASDAQ:RNAZ – Get Free Report) released its quarterly earnings results on Monday. The company reported ($9.19) earnings per share (EPS) for the quarter, Zacks reports.

TransCode Therapeutics Price Performance

Shares of TransCode Therapeutics stock traded down $0.07 during trading hours on Wednesday, hitting $1.33. 16,601 shares of the company’s stock traded hands, compared to its average volume of 104,460. TransCode Therapeutics has a 12-month low of $1.28 and a 12-month high of $12.60. The stock has a market capitalization of $22.60 million, a price-to-earnings ratio of -0.03 and a beta of 1.24. The company has a fifty day simple moving average of $1.64 and a 200-day simple moving average of $5.65.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of TransCode Therapeutics in a report on Thursday, October 15th. One equities research analyst has rated the stock with a Sell rating. Based on data from MarketBeat, TransCode Therapeutics presently has an average rating of “Sell”.

Get Our Latest Research Report on TransCode Therapeutics

About TransCode Therapeutics

(Get Free Report)

TransCode Therapeutics is a clinical-stage biotechnology company developing RNA-based medicines for cancer, with a focus on metastatic disease. Its research centers on using RNA therapeutics to target biological processes involved in cancer growth and spread. The company’s lead program, TTX-MC138, is designed to inhibit microRNA-10b, a molecule associated with cancer metastasis. TransCode is also advancing other investigational RNA-based programs aimed at cancer-related targets. These candidates remain in development and are not approved treatments.

Read More

Earnings History for TransCode Therapeutics (NASDAQ:RNAZ)

Receive News & Ratings for TransCode Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransCode Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.